BioLamina

BioLamina manufactures full-length human recombinant laminins for primary and stem-cell culture applications. The company's product portfolio includes recombinant laminins as cell culture matrices for pluripotent stem cell culture, early epithelial development, differentiation, and screening kits. Founded in 2008 and headquartered in Sundbyberg, Sweden, BioLamina has raised approximately $18.2M in Series B funding from investors including Lauxera Capital Partners, Bure Equity, Northislet, and the European Investment Bank. The company's laminin-based matrices provide biologically relevant substrates that mimic the natural extracellular environment, enabling researchers to culture cells with improved consistency and physiological relevance for regenerative medicine, drug discovery, and cell therapy development.